Veru (NASDAQ:VERU – Get Free Report) posted its earnings results on Monday. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01, Zacks reports. Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%.
Veru Stock Performance
Shares of NASDAQ:VERU opened at $0.71 on Wednesday. Veru has a one year low of $0.36 and a one year high of $1.92. The stock has a market capitalization of $104.42 million, a price-to-earnings ratio of -1.49 and a beta of -0.50. The company has a 50-day simple moving average of $0.75 and a 200-day simple moving average of $0.82.
Wall Street Analysts Forecast Growth
Separately, Oppenheimer reiterated an “outperform” rating and issued a $5.00 price objective on shares of Veru in a research note on Tuesday, November 5th.
Veru Company Profile
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Featured Articles
- Five stocks we like better than Veru
- What is a support level?
- 3 Stocks J.P. Morgan Just Upgraded and Why They’re Bullish
- Market Cap Calculator: How to Calculate Market Cap
- Trump’s China Tariffs Could Reshape These 2 Semiconductor Stocks
- What is MarketRank™? How to Use it
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.
